[1] HOTAMISLIGIL G S. Inflammation and metabolic disorders[J]. Nature, 2006, 444(7121):860-867. [2] DONATH M Y, SHOELSON S E. Type 2 diabetes as an inflammatory disease[J]. Nat Rev Immunol, 2011, 11(2):98-107. [3] XI L, XIAO C, BANDSMA R. C-reactive protein impairs hepatic activated protein kinases[J]. Hepatology, 2011, 53(1):127-135. [4] FASSHAUER M, BLVHER M. Adipokines in health and disease[J]. Trends Pharmacol Sci, 2015, 36(7):461-470. [5] RABE K, LEHRKE M, PARHOFER K G, et al. Adipokines and insulin resistance[J]. Mol Med, 2008, 14(11/12):741-751. [6] FENG Y H, CHEN L, LUO Q, et al. Involvement of microRNA-146a in diabetic peripheral neuropathy through the regulation of inflammation[J]. Drug Des Devel Ther, 2018, 12:171-177. [7] WANG N, XU T Y, ZHANG X, et al. Improving hyperglycemic effect of FGF-21 is associated with alleviating inflammatory state in diabetes[J]. Int Immunopharmacol, 2018, 56:301-309. [8] 雍履平. 五味子治疗糖尿病功效卓著[J]. 中医杂志, 1998, 39(7):389. [9] JIN D, ZHAO T, FENG W W, et al. Schisandra polysaccharide increased glucose consumption by up-regulating the expression of GLUT-4[J]. Int J Biol Macromol, 2016, 87:555-562. [10] AN L P, WANG Y P, WANG C M, et al. Protective effect of Schisandrae chinensis oil on pancreatic β-cells in diabetic rats[J]. Endocrine, 2015, 48(3):818-825. [11] WANG C M, YUAN R S, ZHUANG W Y, et al. Schisandra polysaccharide inhibits hepatic lipid accumulation by downregulating expression of SREBPs in NAFLD mice[J]. Lipids Health Dis, 2016, 15(1):195. [12] PARK H J, LEE S J, SONG Y, et al. Schisandra chinensis prevents alcohol-induced fatty liver disease in rats[J]. J Med Food, 2014, 17(1):103-110. [13] YUAN R S, TAO X, LIANG S, et al. Protective effect of acidic polysaccharide from Schisandra chinensis on acute ethanol-induced liver injury through reducing CYP2E1-dependent oxidative stress[J]. Biomed Pharmacother, 2018, 99:537-542. [14] TAO X, LIANG S, CHE J, et al. Antidiabetic activity of acidic polysaccharide from schisandra chinensisin STZ-Induced diabetic mice[J]. Nat Prod Commun,2019,14(6).DOI:10.1177/1934578X19850374. [15] ZHANG M, LV X Y, LI J, et al. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model[J]. Exp Diabetes Res, 2008, 2008:704045. [16] VEERAPUR V P, PRABHAKAR K R, THIPPESWAMY B S, et al. Antidiabetic effect of Ficus racemosa Linn. stem bark in high-fat diet and low-dose streptozotocin-induced type 2 diabetic rats:A mechanistic study[J]. Food Chem, 2012, 132(1):186-193. [17] 张志军. 五味子治疗糖尿病的效果[J]. 国外医学:中医中药分册, 1994, 16(3):27-28. [18] NIU J M, XU G Y, JIANG S, et al. In vitro antioxidant activities and anti-diabetic effect of a polysaccharide from Schisandra sphenanthera in rats with type 2 diabetes[J]. Int J Biol Macromol, 2017, 94(Pt A):154-160. [19] AKASH M S, REHMAN K, CHEN S Q. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus[J]. J Cell Biochem, 2013, 114(3):525-531. [20] KOHLGRUBER A, LYNCH L. Adipose tissue inflammation in the pathogenesis of type 2 diabetes[J]. Curr Diab Rep, 2015, 15(11):92. [21] HOTAMISLIGIL G S, SHARGILL N S, SPIEGELMAN B M. Adipose expression of tumor necrosis factor-α:direct role in obesity-linked insulin resistance[J]. Science, 1993, 259(5091):87-91. [22] LUMENG C N, BODZIN J L, SALTIEL A R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization[J]. J Clin Invest, 2007, 117(1):175-184. [23] EGUCHI K, NAGAI R. Islet inflammation in type 2 diabetes and physiology[J]. J Clin Invest, 2017, 127(1):14-23. [24] MARCHETTI P. Islet inflammation in type 2 diabetes[J]. Diabetologia, 2016, 59(4):668-672. [25] EGUCHI K, MANABE I. Macrophages and islet inflammation in type 2 diabetes[J]. Diabetes Obes Metab, 2013, 15(Suppl):152-158. [26] LONTCHI Y, SOBNGWI E, MATSHAT E, et al. Diabetes Mellitus and Inflammation[J]. Curr Diab Rep, 2013, 13(3):435-444. [27] LARSEN C M, FAULENBACH M,VAAG A,et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus[J]. N Engl J Med, 2007, 356(15):1517-1526. [28] SLOAN-LANCASTER J,ABU-BADDADE,POLZER J,et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes[J]. Diabetes Care, 2013, 36(8):2239-2246. [29] GOLDFINE A B,FONSECA V, JABLONSKI K A,et al. Salicylate (salsalate) in patients with type 2 diabetes:A randomized trial[J]. Ann Intern Med, 2013, 159(1):1-12. |